Yes...I received this last week from LPTN
We received the full data last week and are in the process of performing a large number of analyses that might help us understand the reasons for the unexpected results of the Nexus trial.
It will probably take at least a few weeks to complete that review of all the data. We plan to share the results of these analyses with our investors when they have been completed.
Regarding next steps: We reduced our workforce from 28 to 15, and made other changes to reduce spending and refocus priorities. We have sufficient cash to support our planned research and development activities through March 31, 2016.
Reasons for optimism:
1. We have a molecule (ASONEP) that has proven very safe in the clinic and has shown signs of activity. In the Phase 2a renal cell carcinoma trial 35% of patients experienced stable disease for 4 months or longer. Five patients remain on that trial, all of whom have maintained stable disease for at least six months and some have exceeded 20 months.
2. We have a second molecule (Lpathomab) that is ready to begin Phase 1 trials as a treatment for neuropathic pain.
3. Both of these molecules have a number of additional potential indications that we are pursuing.
4. In addition, we have a pipeline that includes Altepan, a drug candidate that has shown promising results in preclinical models of asthma and inflammatory bowel disease. Altepan is ready to start formal development activities when funding is available.
5. We also have another series of antibody candidates against another lipid target.
6. In addition we have expanded our technology platform increasing the likelihood of obtaining quality antibodies against difficult targets.
The key remains that we need definitive clinical proof of concept for this technology, and our plan prioritizes those programs that can enable us to achieve that as rapidly as we can.
News 
Market Data 
Discover 
